Guardian Wealth Advisors LLC Has $322,000 Stock Position in Medtronic PLC $MDT

Guardian Wealth Advisors LLC lessened its stake in shares of Medtronic PLC (NYSE:MDT) by 3.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,688 shares of the medical technology company’s stock after selling 137 shares during the period. Guardian Wealth Advisors LLC’s holdings in Medtronic were worth $322,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in MDT. Blake Schutter Theil Wealth Advisors LLC increased its position in shares of Medtronic by 12.1% in the second quarter. Blake Schutter Theil Wealth Advisors LLC now owns 5,470 shares of the medical technology company’s stock worth $477,000 after acquiring an additional 590 shares in the last quarter. Ballast Advisors LLC lifted its position in shares of Medtronic by 73.5% in the 2nd quarter. Ballast Advisors LLC now owns 8,939 shares of the medical technology company’s stock valued at $779,000 after acquiring an additional 3,788 shares in the last quarter. University of Texas Texas AM Investment Management Co. boosted its stake in Medtronic by 63.7% in the 2nd quarter. University of Texas Texas AM Investment Management Co. now owns 118,549 shares of the medical technology company’s stock worth $10,334,000 after purchasing an additional 46,114 shares during the period. Whipplewood Advisors LLC grew its position in Medtronic by 11.5% during the 2nd quarter. Whipplewood Advisors LLC now owns 1,452 shares of the medical technology company’s stock worth $127,000 after purchasing an additional 150 shares in the last quarter. Finally, Interchange Capital Partners LLC grew its position in Medtronic by 19.2% during the 2nd quarter. Interchange Capital Partners LLC now owns 3,266 shares of the medical technology company’s stock worth $285,000 after purchasing an additional 527 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Medtronic

In related news, Director William R. Jellison bought 2,500 shares of the business’s stock in a transaction on Monday, August 25th. The shares were bought at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the acquisition, the director directly owned 5,000 shares in the company, valued at approximately $461,850. This represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Harry Skip Kiil sold 8,605 shares of the company’s stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the sale, the executive vice president owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.26% of the company’s stock.

Medtronic Price Performance

MDT opened at $93.76 on Friday. The stock has a fifty day moving average price of $94.32 and a 200 day moving average price of $89.39. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $99.37. The stock has a market cap of $120.26 billion, a price-to-earnings ratio of 25.83, a PEG ratio of 2.47 and a beta of 0.78.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.03. The company had revenue of $8.58 billion during the quarter, compared to the consensus estimate of $8.37 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The business’s quarterly revenue was up 7.7% on a year-over-year basis. During the same period last year, the business earned $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 17th. Shareholders of record on Friday, September 26th were given a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend was Friday, September 26th. Medtronic’s payout ratio is currently 78.24%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Stifel Nicolaus increased their target price on Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a report on Thursday, October 9th. Wells Fargo & Company upped their price target on Medtronic from $98.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, August 20th. Robert W. Baird raised their price objective on Medtronic from $94.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 20th. Morgan Stanley reaffirmed an “overweight” rating and set a $107.00 target price (up previously from $98.00) on shares of Medtronic in a research note on Tuesday, July 15th. Finally, Wolfe Research upgraded Medtronic from an “underperform” rating to a “peer perform” rating in a report on Monday, June 30th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $102.82.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.